The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 15, 2025
Filed:
Jul. 27, 2018
Applicant:
Scholar Rock, Inc., Cambridge, MA (US);
Inventors:
Thomas Schurpf, Cambridge, MA (US);
Christopher Littlefield, Marblehead, MA (US);
Gregory J. Carven, Maynard, MA (US);
Abhishek Datta, Boston, MA (US);
Assignee:
Scholar Rock, Inc., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/00 (2006.01); C07K 16/22 (2006.01); G01N 33/531 (2006.01); G01N 33/537 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); C07K 16/22 (2013.01); G01N 33/531 (2013.01); G01N 33/537 (2013.01); A61K 2039/545 (2013.01); C07K 2317/10 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01);
Abstract
Disclosed herein are inhibitors, such as antibodies, and antigen binding portions thereof, that selectively bind complexes of LTBP1-TGFβ1 and/or LTBP3-TGFβ1. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFβ1 activation, and treating subjects suffering from TGFβ1-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGFβ1 inhibitor for a subject in need thereof are also provided.